Cyramza® New Indication

June 1, 2020

Cyramza® New Indication

The FDA has announced that Cyramza® (ramucirumab) is now approved in combination with erlotinib as a first-line treatment for non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.1

Prescribers can immediately place prescription orders with Onco360 for CYRAMZA as well as other cancer and supportive care medications

For more information on Cyramza, please visit cyramza.com.